ClinicalTrials.gg
Active, not recruitingNCT04603898Updated Jun 9, 2026

Oxalate Formation From Ascorbic Acid

An interventional study of Low Oxalate Diet and Carbon-13 Ascorbic Acid Oral Load in Kidney Stone, sponsored by University of Alabama at Birmingham. Active, not recruiting at 1 site in United States. Open to participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-09.

Sponsored by University of Alabama at Birmingham · Not applicable, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Not applicable
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Kidney Calculi by University of Alabama at Birmingham — 6 open to participants now, 12 under way, none of them phase 3. Kidney Calculi · University of Alabama at Birmingham.

Enrollment
Largest of 17
90 · median 40
Started
2021
with 3 others
No phase
17 of 17
6 open now
Primary completion
2026-12
later than 2 of 11 live
Registered
10th of 17
by date

Among the 17 studies in Kidney Calculi by University of Alabama at Birmingham, this one has the largest enrollment, is one of 4 that started in 2021, is one of 17 with no phase, reaches primary completion later than 2 of the 11 other live ones, and was the 10th registered.

Kidney Calculi

510 studies on the registry are indexed under Kidney Calculi; 147 are open to participants now.

Browse Kidney Calculi studies →

Open to participants now

6 of the 17 studies in Kidney Calculi by University of Alabama at Birmingham are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 88 Kidney Calculi studies recruiting now, 48 (55%) set no upper age limit and 23 (26%) stop at 75 or younger; 6 take children under 18; 11 take healthy volunteers.

This study: 19 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Kidney Calculi by University of Alabama at Birmingham, or all of them as a file.
02

Study summary

The purpose of this basic research study is to determine the contribution of endogenous ascorbic acid (AA) turnover to urinary oxalate excretion in both normal BMI and obese adult non-stone formers and calcium oxalate stone formers. The studies proposed will use diets of known nutrient composition, a stable isotope of ascorbic acid (13C6-AA) and mass spectrometric techniques to quantify ascorbic acid turnover to oxalate.

Read the detailed description

The purpose of this basic research study is to determine the contribution of endogenous ascorbic acid (AA)turnover to urinary oxalate excretion in both normal BMI and obese adult non-stone formers and calcium oxalate stone formers. The studies proposed will use diets of known nutrient composition, a stable isotope of AA, 13C6-AA, and mass spectrometric techniques to quantify AA turnover to oxalate.

Adults (≥19 years) with and without a history of calcium oxalate kidney stone disease will be recruited from within the greater Birmingham area, and divided into normal BMI (BMI\<25 kg/m2) and obese (BMI≥30 kg/m2) groups. Following consent, subjects will meet with a dietitian to ensure willingness to consume controlled diets, and provide fasted blood and 2 x 24 hour urine specimens to determine general health status and adequacy of 24-hour urine collections, respectively.

Eligible subjects will consume a low oxalate controlled diet for 6 days, which will involve 2 days of dietary equilibration followed by oral ingestion of 1 mg/kg carbon-13 AA with breakfast on day 3 and subsequent collection of 4 consecutive 24-hour urine specimens. After the carbon-13 AA load, subjects will return each morning to the Clinical Research Unit for a fasted blood draw, to drop off their 24-hour urine collection, and receive their prepared food. In addition, on day 4, 24 hours after ingesting carbon-13 AA, subjects will collect hourly urine and 1/2 hourly blood samples for 5 hours in the Clinical Research Unit.

03

Conditions studied

  • Kidney Stone

Browse trials for

Keywords

  • Oxalate
  • Calcium oxalate stones
  • Ascorbic Acid
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to provide
  • For stone formers: composition of most recent stone > 50% calcium oxalate, no uric acid component
  • For stone formers: first time or recurrent calcium oxalate stone former with stone event within the prior 3 years
  • Two 24-hour urine collections with urinary 24-hour creatinine excretion within 20% of appropriate ratio of creatinine (mg) / body weigh (kg) for gender
  • Willingness to stop supplements (vitamins, Calcium (citrate or carbonate) and other minerals, herbal supplements, nutritional aids, probiotics) for 2 weeks before start and during study
  • Willingness to not undertake vigorous exercise during the study
  • Normal fasting blood Comprehensive Metabolic Panel (CMP)
  • Willingness to ingest menus prepared in Clinical Research Unit at University of Alabama at Birmingham
  • No food allergies or intolerance to any of the foods in study menus
  • If on medications for stone prevention (e.g. thiazides, citrate supplementation excluding calcium citrate), they should have been on a stable dose regimen for at least 8 weeks prior to and during screening, with no changes in dosing anticipated during study protocol. If on allopurinol for stone prevention, stop it for 2 weeks prior to screening and this will not be administered during the study as it has anti-oxidant properties.

Exclusion criteria

Exclusion Criteria:

  • Diabetes
  • Gout
  • Hypertension
  • Estimated (eGFR) less than 60ml/min/1.73m2
  • Primary hyperoxaluria
  • Nephrotic syndrome
  • Enteric hyperoxaluria
  • Renal tubular acidosis
  • Primary hyperparathyroidism
  • Liver disease
  • Auto-immune disorder
  • Neurogenic bladder
  • Urinary diversion
  • Bariatric surgery
  • Active or treatment for malignancy within 12 months prior to screening
  • Pregnancy
  • Breastfeeding/nursing individuals
  • Females of child bearing age who are not able to use an effective method of during the study
  • Mental/medical condition that is likely to impede successful study completion
  • Illness including flu/common cold/fever 14 days before study and during study
  • Diarrhea or other abnormal gastrointestinal event (e.g. abnormal bowel movements) 14 days before study or during study
  • Abnormal fasting CMP
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
90 participants (actual)

Study arms

  • Experimental
    Controlled Dietary Study

    Subjects will consume a controlled diet (low in oxalate and ascorbic acid) for six days. After two days of equilibration, subjects will provide a blood sample and ingest an oral load of ascorbic acid (1 mg/kg) with breakfast on Day 3. The following day (Day 4), serial blood and urine collections will occur. On Days 5 through 7, subjects will complete a 24-hr urine collection and blood draw.

    Dietary Supplement: Low Oxalate Diet · Dietary Supplement: Carbon-13 Ascorbic Acid Oral Load

Interventions

  • Dietary supplementLow Oxalate Diet

    Subjects will be instructed to ingest a controlled diet low in oxalate for a total of 4 days

  • Dietary supplementCarbon-13Studies of Carbon-13Carbon-13 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Subjects will be instructed to ingest 1mg/kg of carbon-13 ascorbic acid at breakfast, 2 days after initiating the low oxalate controlled diet.

06

What researchers measure

Primary outcomes

  1. Percent contribution of ascorbic acid (AA) to urinary oxalate excretion

    On the last day (Day 4) of controlled diet and 24 hours following ingestion of an oral load of carbon-13 AA (1mg/kg), urine and blood will be collected and the levels of carbon 12 and carbon 13 AA and oxalate measured to determine the percent contribution of AA metabolism to urinary oxalate excretion for each subject.

    Time frame: Day 4

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2021 (actual). Primary completion is estimated for Dec 2026, 60 months after the start.

Of 183 non-industry interventional studies with no phase under Kidney Calculi, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 54. This study's planned 60 months is above that.

Counting every sponsor, half of 199 studies reached it within 26 months; a quarter within 12 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2020
First posted
Oct 27, 2020
StartActual
Nov 15, 2021
Primary completionEst.
Dec 1, 2026
CompletionEst.
Feb 1, 2027
Last update
Jun 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04603898
Responsible party
John Knight (Principal Investigator, University of Alabama at Birmingham) — Principal investigator
First posted
Oct 27, 2020
Start date
Nov 15, 2021
Primary completion
Dec 1, 2026 (estimated)
Completion
Feb 1, 2027 (estimated)
Last update
Jun 9, 2026

Study contacts

John Knight, PhD
principal investigator · University of Alabama at Birmingham

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Carbon-13

Start the discussion